
Contents

Preface	XI
-------------------	----

Pharmacological Background of the Therapeutic Activities and Side Effects of Calcium Antagonists

P. A. van Zwieten, Amsterdam, The Netherlands	1
Introduction	1
Nomenclature and Definitions	1
Chemistry	3
Radioligand-Binding Studies	5
Calcium Channels	6
Pharmacology	7
Organ Specificity	9
Pharmacological Background of Therapeutic Applications	10
Cardiovascular Disease	10
Calcium Antagonists in the Treatment of Neurological Disease	12
Pharmacological Background of Adverse Reactions	15
Dihydropyridines	15
Verapamil and Gallopamil	15
Diltiazem	16
Flunarizine	16
Conclusions	17
References	17

Hemodynamic Actions of Calcium Entry Blockers

H. A. J. Struyker-Boudier, J. G. De Mey, J. F. M. Smits, H. M. N. W. Nieuvelstein, Maastricht	21
Introduction	21
The Cardiovascular System and Its Control Mechanisms	22

Vascular Effects of Calcium Entry Blockers	23
Effects on Isolated Blood Vessels	23
Calcium Entry Blockers and Vascular -adrenoceptors	25
Does the Endothelium Play a Role in the Vascular Effects of Calcium Entry Blockers?	28
In Vivo Vascular Effects of Calcium Entry Blockers	28
Cardiac Effects of Calcium Entry Blockers	39
Effects on Myocardial Contractility	39
Effects on Nodal Tissue	40
Effects on Coronary Vascular Tone	40
Effects on Cardiac Metabolism and Damage due to Ischemia	41
Effects of Calcium Entry Blockers on Cardiovascular Control Mechanisms	42
Nervous Control of the Circulation	42
Endocrine Control of the Circulation	44
Renal Control of the Circulation	45
Long-Term Control by Structural Design of the Cardiovascular System	48
Synthesis: The Overall Hemodynamic Effects of Calcium Entry Blockers	49
References	51

Calcium Antagonism in the Control of Cardiac Arrhythmias

B. N. Singh, Los Angeles, Calif.	67
Electropharmacologic Considerations	67
Clinical Electrophysiologic Effects of Calcium Antagonists	68
Effects of Calcium Antagonists in Supraventricular Arrhythmias	69
Acute Termination of Paroxysmal Supraventricular Tachycardia	70
Modes of Conversion of Paroxysmal Supraventricular Tachycardia with Calcium Antagonists	71
Acute Conversion of Paroxysmal Supraventricular Tachycardia: Calcium Antagonists versus Other Antiarrhythmic Agents	72
Calcium Antagonists versus Adenosine and Adenosine Triphosphate in the Acute Conversion of Paroxysmal Supraventricular Tachycardia	73
Response in Other Forms of Reentrant of Ectopic Supraventricular Tachycardia	73
Calcium Antagonist and Multifocal Tachycardia	73
Chronic Prophylaxis of Paroxysmal Supraventricular Tachycardia with Calcium Antagonists	74
Verapamil and Paroxysmal Atrial Tachycardia with Block	75
Calcium Antagonists in Preexcitation Syndroms	75
Treatment of Other Atrial Tachyarrhythmias by Calcium Antagonists	76
Atrial Fibrillation	76
Maintenance of Sinus Rhythm	78
Atrial Flutter	78
Ventricular Arrhythmias	78
Premature Ventricular Contractions	79

Chronic Recurrent Ventricular Tachycardia	79
Exercise-Triggered Ventricular Tachycardia	81
Idiopathic Ventricular Tachycardia with Right Bundle Branch Block and Left Axis Deviation Morphology	81
Torsades de Pointe and Calcium Antagonism	82
Calcium Antagonists and Sudden Death	82
Summary and Conclusions	83
References	84

Treatment of Myocardial Ischemia with Calcium Entry Blockers

W. H. van Gilst, K. I. Lie, Groningen, The Netherlands	88
Introduction	88
Pathogenetic Classification of Ischemic Heart Disease	88
Results of Controlled Trials with Calcium Entry Blockers in Relatively 'Stable' Ischemic Syndromes, i. e. Stable and Mixed Angina	90
Results of Controlled Trials with Calcium Entry Blockers in Acute Unstable Ischemic Syndromes, i. e. Unstable Angina and Myocardial Infarction	93
Unstable Angina	93
Acute Myocardial Infarction	94
Conclusions	98
References	98

Treatment of Hypertension with Calcium Antagonists

L. Hansson, B. Dahlöf, Göteborg, Sweden	103
Background	103
Nomenclature	103
Calcium and Hypertension	104
Early Use of Calcium Antagonists in Hypertension	105
Chemistry – Pharmacology – Pharmacokinetics	105
Effects in Hypertension	106
Hemodynamics.	106
Mode of Action.	108
Antihypertensive Effect	109
Effects on Cardiovascular Structure	111
Additional Effects	112
Adverse Effects	112
Interactions	113
Indications	114

Contraindications	115
Socio-Economic Aspects	116
Compliance	116
Cost	116
Future Aspects	116
References	117

*Clinical Aspects of Calcium Entry Blockers in Cardiomyopathy,
Primary Pulmonary Hypertension and Raynaud's Phenomenon*

M. P. Frenneaux, W.J. McKenna, D. M. Krikler, London, U.K.	125
Hypertrophic Cardiomyopathy	125
Experience with Verapamil	126
Invasive Haemodynamic Studies	129
Experience with Nifedipine	130
Raynaud's Phenomenon	131
Primary Pulmonary Hypertension	132
Cardiac Failure	134
References	136

Treatment of Migraine with Calcium Entry Blockers

P. Tfelt-Hansen, L. Edvinsson, J. Olesen, Copenhagen, Denmark	143
Introduction	143
Flunarizine	144
Placebo-Controlled Trials	144
Comparative Trials	144
Other Studies	147
Nimodipine	147
Placebo-Controlled Trials	147
Comparative Trials	147
Other Studies	148
Verapamil	148
Diltiazem	149
Discussion	149
Review of Trials	149
Mode of Action	150
Clinical Implications	151
References	152

*Treatment of Neurological Disorders Except Migraine with
Calcium Antagonists*

A. Hartmann, Bonn; P. A. van Zwieten, Amsterdam	155
Events at the Cellular Level Associated with Cerebral Ischemia	155
Subarachnoidal Hemorrhage.	159
Pathophysiology and Biochemistry	159
Prevention of Vasospasms	162
Treatment of Existing Vasospasms	165
Cerebral Infarction.	166
Calcium-Antagonists and Global Cerebral Ischemia	169
Vertebrobasilar Insufficiency and Vertigo	173
Epilepsy	174
Conclusions	175
References	177
Subject Index	195